Takeda oncology vet drills down the ‘basics’ at cell therapy startup; Sarepta promotes new R&D chief

Kathryn Corzo

Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite.

The newest member at cell therapy player bit.bio as their COO, the longtime drug developer left Takeda (where she served, in turn, as the head of oncology cell therapy and then a partner in its venture arm) to join the small biotech. For Corzo, bit.bio presented a unique opportunity to try and solve issues that had been plaguing cell therapy — and one of the three reasons why she left Takeda.

Aside from bit.bio’s cell coding platforms and “their ability to pretty much target any human cell,” according to Corzo, she left Takeda to both leverage her experience in drug development and build upon skills that she learned at MIT just a few years prior, while getting…
Click here to view original post